Author:
Oliver Sara E.,Wallace Megan,See Isaac,Mbaeyi Sarah,Godfrey Monica,Hadler Stephen C.,Jatlaoui Tara C.,Twentyman Evelyn,Hughes Michelle M.,Rao Agam K.,Fiore Anthony,Su John R.,Broder Karen R.,Shimabukuro Tom,Lale Allison,Shay David K.,Markowitz Lauri E.,Wharton Melinda,Bell Beth P.,Brooks Oliver,McNally Veronica,Lee Grace M.,Talbot H. Keipp,Daley Matthew F.
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology
Reference10 articles.
1. Food and Drug Administration. Janssen COVID-19 vaccine emergency use authorization. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/Janssen-covid-19-vaccine
2. The Advisory Committee on Immunization Practices’ interim recommendation for use of Janssen COVID-19 vaccine—United States, February 2021.;Oliver;MMWR Morb Mortal Wkly Rep,2021
3. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients—United States, April 2021.;MacNeil;MMWR Morb Mortal Wkly Rep,2021
4. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021.;Gargano;MMWR Morb Mortal Wkly Rep,2021
5. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices—United States, July 2021.;Rosenblum;MMWR Morb Mortal Wkly Rep,2021